RELIEF Therapeutics Holding AG Logo

RELIEF Therapeutics Holding AG

ISIN

CH0100191136

Ticker

RLF

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Switzerland

Year Founded

2013

About RELIEF Therapeutics Holding AG

Company Description

Relief is a biopharmaceutical company whose objective is to provide patients with therapeutic RELIEF in serious diseases with high unmet medical need.

We focus on clinical-stage programs based on molecules with a history of clinical use (well-established safety and tolerability) and either initial human activity or efficacy data (proof of concept) or a strong scientific rationale. This allows us to identify molecules where clinical development can be swift (trials with evaluation windows of weeks or months) and cost effective. Our lead compound is RLF-100™, a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action, for respiratory indications. The development program currently is focused on COVID-19-induced severe lung injury and pulmonary sarcoidosis. These are two diseases for which an unmet medical need exists. Clinical development opportunities of RLF-100™ for other indications in both acute and chronic lung diseases are being evaluated.

Served Area

Worldwide

Headquarters

Avenue de Sécheron 15
1202, Genève
Switzerland

Capital Markets Information

ISIN

CH0100191136

LEI

506700IT19260EVD7916

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

SIX Swiss Exchange

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.